SCHEMBL5010884

SCHEMBL5010884

COc1cccc(C2CNC(=O)OC23CCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC3)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RHOA P61586 1/20 0.47
USP2 O75604 9/20 0.47
CYP3A4 P08684 8/20 0.47
CYP2C9 P11712 3/20 0.46
ALDH1A1 P00352 2/20 0.46
PLD2 O14939 1/20 0.45
PLD1 Q13393 1/20 0.45
TSHR P16473 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HIF1A Q16665 2/20 0.43
MGLL Q99685 1/20 0.43
CCR2 P41597 1/20 0.42
KCNH2 Q12809 1/20 0.42
MAPK1 P28482 1/20 0.42
TACR1 P25103 1/20 0.42
HSD17B10 Q99714 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010886 1.00 RHOA (0.47) RHOAUSP2CYP3A4CYP2C9ALDH1A1
SCHEMBL5012152 0.87 CYP3A4 (0.53) USP2CYP3A4CYP2C9ALDH1A1TSHR
SCHEMBL5010920 0.87 CYP3A4 (0.53) USP2CYP3A4CYP2C9ALDH1A1TSHR
SCHEMBL5014232 0.87 CYP3A4 (0.46) RHOAUSP2CYP3A4CYP2C9ALDH1A1
SCHEMBL5012629 0.87 CYP3A4 (0.46) RHOAUSP2CYP3A4CYP2C9ALDH1A1
SCHEMBL7219705 0.84 HIF1A (0.46) USP2CYP3A4CYP2C9ALDH1A1PLD2
SCHEMBL7219708 0.84 HIF1A (0.46) USP2CYP3A4CYP2C9ALDH1A1PLD2
SCHEMBL5010895 0.83 TSHR (0.46) RHOAUSP2CYP3A4CYP2C9ALDH1A1
SCHEMBL5012597 0.83 TSHR (0.46) RHOAUSP2CYP3A4CYP2C9ALDH1A1
SCHEMBL5012620 0.82 USP2 (0.43) RHOAUSP2CYP3A4CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390372-B1 1-OXA-3,9-DIAZA-SPIRO'5,5]UNDECAN-2-ONES DERIVATIVES AND ITS USE AS ANTAGONIST OF THE NEURIKININ RECEPTOR HOFFMANN LA ROCHE (CH) 2008-07-16 EP disclosed
US-6599900-B2 Antiinflammatory agents; headaches; antiarthritic agents SYNTEX (U.S.A.) LLC 2003-07-29 US disclosed
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones SYNTEX (U.S.A) LLC 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones OXER1, NR4A1, OXGR1 RHOA 4751/4885USP2 4097/4885CYP3A4 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.